Zagorodnyuk V, Maggi C A
Department of Neuromuscular Physiology, Bogomoletz Institute of Physiology, Kiev, Ukraine.
Neuroscience. 1995 Nov;69(2):643-50. doi: 10.1016/0306-4522(95)00271-j.
The aims of this study were: (i) verify the usefulness of the recently described non-peptide antagonist, SR 142801, for blocking tachykinin NK3 receptors in the circular muscle of the guinea-pig colon and (ii) after occlusion of NK3 receptors by SR 142801, test the hypothesis that tachykinins may activate non-adrenergic non-cholinergic inhibitory neurons via non-NK3 receptors. In sucrose gap, we found that SR 142801 (0.1 microM) time-dependently inhibited the senktide-induced atropine (1 microM)-sensitive depolarization, action potentials and contractions of circular muscle of guinea-pig colon without affecting the cholinergic excitatory junction potential and contraction produced by single pulse electrical field stimulation. Likewise, SR 142801 (0.1 microM) time-dependently inhibited the senktide-induced non-adrenergic non-cholinergic hyperpolarization and relaxation of the circular muscle, without affecting the non-adrenergic non-cholinergic inhibitory junction potentials and relaxation produced by single pulse electrical field stimulation. Therefore, SR 142801 is a suitable tool to occlude neuronal NK3 receptors in guinea-pig colon. In the presence of SR 142801 (0.1 microM), atropine (1 microM), guanethidine (3 microM), indomethacin (3 microM) and nifedipine (1 microM) superfusion with neurokinin A (0.3 microM) produced depolarization on which a series of inhibitory junction potentials were superimposed. The incidence, number and amplitude of the inhibitory junction potentials evoked by neurokinin A was partly reduced by pretreatment with either apamin (0.1 microM) or L-nitroarginine (30 microM) and was totally blocked by pretreatment with apamin plus L-nitroarginine or by tetrodotoxin (1 microM). None of these treatments affected the depolarization and contraction produced by neurokinin A. The NK1 receptor selective antagonist, GR 82,334 (3 microM), did not affect the responses to neurokinin A, which were abolished by the NK2 receptor-selective antagonist GR 94,800 (0.1 microM). Substance P (0.3 microM) produced a large depolarization of the membrane but was poorly effective in producing superimposed inhibitory junction potentials. The NK1 receptor-selective agonist [Sar9]substance P sulfone (0.3 microM) produced large depolarization without inducing superimposed inhibitory junction potentials, while the NK2 receptor-selective synthetic agonist [beta-Ala8]neurokinin A(4-10) (0.3 microM) produced depolarization and superimposed inhibitory junction potentials. We conclude that neurokinin A, in addition to direct excitation and contraction of circular muscle activates, via neuronal NK2 receptors, inhibitory non-adrenergic non-cholinergic motorneurons. Thus, neuronal NK2 receptors should be considered as targets for endogenous tachykinins in enteric circuitries leading to descending relaxation in guinea-pig colon.
(i)验证最近描述的非肽拮抗剂SR 142801对阻断豚鼠结肠环行肌中速激肽NK3受体的有效性,以及(ii)在SR 142801阻断NK3受体后,检验速激肽可能通过非NK3受体激活非肾上腺素能非胆碱能抑制性神经元的假说。在蔗糖间隙实验中,我们发现SR 142801(0.1微摩尔)能时间依赖性地抑制速激肽诱导的阿托品(1微摩尔)敏感的去极化、动作电位以及豚鼠结肠环行肌的收缩,而不影响胆碱能兴奋性接头电位以及单脉冲电场刺激所产生的收缩。同样,SR 142801(0.1微摩尔)能时间依赖性地抑制速激肽诱导的非肾上腺素能非胆碱能超极化以及环行肌的舒张,而不影响单脉冲电场刺激所产生的非肾上腺素能非胆碱能抑制性接头电位及舒张。因此,SR 142801是阻断豚鼠结肠神经元NK3受体的合适工具。在存在SR 142801(0.1微摩尔)、阿托品(1微摩尔)、胍乙啶(3微摩尔)、吲哚美辛(3微摩尔)和硝苯地平(1微摩尔)的情况下,用神经激肽A(0.3微摩尔)进行灌流会产生去极化,在此基础上叠加一系列抑制性接头电位。神经激肽A诱发的抑制性接头电位的发生率、数量和幅度,在用蜂毒明肽(0.1微摩尔)或L - 硝基精氨酸(30微摩尔)预处理后会部分降低,而在用蜂毒明肽加L - 硝基精氨酸预处理或用河豚毒素(1微摩尔)预处理后则完全被阻断。这些处理均不影响神经激肽A所产生的去极化和收缩。NK1受体选择性拮抗剂GR 82,334(3微摩尔)不影响对神经激肽A的反应,而NK2受体选择性拮抗剂GR 94,800(0.1微摩尔)则可消除该反应。P物质(0.3微摩尔)可使膜产生较大的去极化,但在产生叠加的抑制性接头电位方面效果不佳。NK1受体选择性激动剂[Sar9]P物质砜(0.3微摩尔)产生较大的去极化但不诱导叠加的抑制性接头电位,而NK2受体选择性合成激动剂[β - Ala8]神经激肽A(4 - 10)(0.3微摩尔)则产生去极化并叠加抑制性接头电位。我们得出结论,神经激肽A除了直接兴奋和收缩环行肌外,还通过神经元NK2受体激活抑制性非肾上腺素能非胆碱能运动神经元。因此,在导致豚鼠结肠下行性舒张的肠内回路中,神经元NK2受体应被视为内源性速激肽的作用靶点。